Why Packaging Format Matters in Stability Studies

The physical and chemical properties of the packaging material directly influence the degradation kinetics of the product. Packaging acts as a barrier against:

• ✓ Moisture (hydrolysis-sensitive APIs)
• ✓ Oxygen (oxidation-prone drugs)
• ✓ Light (photolabile formulations)
• ✓ Volatile impurities or odors

According to ICH Q1A(R2), the packaging used in stability studies must be the same as proposed for commercial distribution, including secondary packaging where it affects stability.

Aluminum Foil Packaging: Strengths and Risks

Aluminum foil is known for its excellent barrier properties against light, moisture, and gases. However, challenges include:

• Delamination: Breakdown of laminate layers in hot/humid conditions
• Chemical reactivity: Especially with acidic or basic drugs when foil is in direct contact
• Pinhole defects: Can allow moisture ingress, leading to false-negative results

To mitigate these risks, foil should be combined with inert layers like polyethylene or PVC and validated under accelerated conditions.

Blister Packs: Alu-Alu vs. Alu-PVC

Blister packaging is common for solid oral dosage forms. Two primary types are:

• Alu-Alu: High barrier to light, moisture, and gases. Suitable for moisture-sensitive APIs.
• Alu-PVC: Lower barrier properties but cost-effective. Risk of moisture ingress over time.

Stability testing must reflect the final packaging type, including individual cavity sealing performance and blister thickness variations.

Flexible Pouch Packaging: Stability Challenges

Pouches are often used for powders, liquids, or multi-dose formats. Risks associated with this format include:

• Seal integrity issues: Heat seal parameters affect air/moisture permeability
• WVTR and OTR concerns: Flexible laminates may allow gradual ingress over time
• Migration of ink or adhesives: Especially when stored under accelerated conditions

Ensure pouch materials pass USP and for water vapor and oxygen transmission rates before use in stability testing.

Case Study: Drug Degradation in Alu-PVC Blister vs. Alu-Alu

A pharmaceutical company evaluated the stability of a moisture-sensitive tablet using two blister formats. After 6 months at 40°C/75% RH, the assay dropped by 8% in Alu-PVC due to moisture ingress, while Alu-Alu retained 99% potency. Based on this result, the sponsor changed to Alu-Alu for all climatic zones.

Checklist for Packaging Stability Evaluation

• ☑ Validate packaging with actual drug product
• ☑ Include foil thickness, blister material type, and pouch lamination layers in protocol
• ☑ Conduct WVTR and OTR testing on packaging samples
• ☑ Evaluate packaging performance at 25°C/60% RH, 30°C/65% RH, and 40°C/75% RH
• ☑ Conduct integrity testing after drop, vibration, and stress simulations

Analytical Testing Considerations

• Moisture content (KF titration for tablets or films)
• Assay and related substances by validated HPLC method
• Photostability per ICH Q1B if blister is transparent
• Visual inspection for blister delamination or seal rupture
• Oxygen content inside pouches using headspace gas analyzers

Documentation for Regulatory Submissions

• Summary of packaging specifications
• Justification for packaging choice based on stability data
• Compatibility study results including leachables/extractables
• Signed reports of WVTR and seal strength tests
• Packaging description in CTD Module 3.2.P.7

Regulatory Insights and Expectations

Agencies such as CDSCO and EMA emphasize packaging consistency between stability batches and commercial lots. It is unacceptable to conduct stability with Alu-Alu blister and market with Alu-PVC unless bridging data is provided.

As per clinical trial protocol requirements, packaging must also be validated during investigational studies to ensure patient safety and data reliability.

Conclusion

Foil wraps, blister packs, and pouches are critical packaging formats, but they come with stability testing complexities. Moisture ingress, seal integrity, and material interaction with the API are common concerns. Through robust packaging evaluation, material qualification, and regulatory alignment, these challenges can be addressed to ensure product quality and shelf life.

References:

• ICH Q1A(R2) Stability Testing Guidelines
• ICH Q1B Photostability Testing
• USP Chapters , , ,
• WHO TRS 1010 Annex 10 – Stability Studies
• FDA Guidance on Container Closure Systems

Step 1: Define the Scope of Compatibility Testing

The first step is to understand the product’s formulation and identify risks posed by container materials:

• Is the product an aqueous, oily, or solvent-based solution?
• Is the drug molecule sensitive to moisture, oxygen, light, or pH changes?
• What are the potential interaction points—adsorption, leaching, permeation?

Define your testing strategy based on these risk factors. High-risk products (e.g., biologicals, injectables, low-dose formulations) require a more comprehensive evaluation.

Step 2: Select Container Materials for Evaluation

Common container materials include:

• Type I borosilicate glass (vials, ampoules)
• HDPE, LDPE, PET (bottles, droppers)
• PVC/PVDC (blister packs)
• Rubber stoppers and elastomeric closures

Collect material safety data sheets (MSDS), supplier specifications, and pharmacopeial compliance documents (e.g., USP or ).

Step 3: Design the Compatibility Testing Protocol

Structure your protocol to cover the following interaction risks:

• Adsorption: Active or excipient adheres to container surface
• Absorption: Product components migrate into the packaging
• Leachables: Container components leach into the product over time
• Permeation: Gases or moisture pass through the container
• Chemical Reaction: Material reacts with formulation ingredients

Refer to ICH Q1A(R2) and ICH Q3D when developing your protocol.

Step 4: Prepare Samples for Compatibility Studies

Fill the drug product into each container variant under aseptic or clean conditions. Label test groups clearly:

• Test Container A: e.g., Type I glass + bromobutyl stopper
• Test Container B: e.g., PET bottle + HDPE cap
• Control: Stored in inert material (e.g., Teflon or amber glass)

Perform initial characterization before placing on stability.

Step 5: Store Samples Under ICH Stability Conditions

Store containers under the following conditions:

• Long-term: 25°C ± 2°C / 60% RH ± 5%
• Accelerated: 40°C ± 2°C / 75% RH ± 5%
• Photostability (if applicable): As per ICH Q1B

Typical duration: 3, 6, and 12-month timepoints. Label and segregate samples carefully to prevent cross-contamination or misidentification.

Step 6: Perform Analytical Testing for Compatibility Indicators

At each stability point, test for:

• Assay and degradation products (HPLC, UV)
• pH, clarity, turbidity, color, odor
• Extractables and leachables (GC-MS, LC-MS, ICP-MS)
• Particulate matter, visible foreign bodies
• Microbial growth (for aqueous or sterile products)

Compare results with acceptance criteria and control samples.

Step 7: Conduct Extractables and Leachables (E&L) Analysis

Extractables and leachables studies are crucial for identifying potentially harmful substances that migrate from container materials into the drug product. Follow these best practices:

• Perform extractables studies using aggressive solvents (water, ethanol, isopropanol, acid, base)
• Use orthogonal detection methods: GC-MS for volatiles, LC-MS for semi-volatiles, ICP-MS for metals
• Design leachables studies using real-time and accelerated stability samples
• Compare migration levels against ICH Q3D and USP thresholds

All data should be compiled in a compatibility risk assessment report for regulatory submissions.

Step 8: Evaluate Container Closure Integrity (CCI)

Container integrity should be tested using validated methods such as:

• Vacuum decay (non-destructive)
• Dye ingress (destructive visual method)
• Helium leak detection (quantitative)
• Microbial ingress (especially for sterile products)

Perform testing before and after exposure to thermal stress, vibration, and humidity to assess mechanical stability.

Step 9: Compile and Interpret Compatibility Study Results

At the end of the stability duration, compare test container results with controls. Interpret findings:

• Did any containers show significant degradation, adsorption, or leachable migration?
• Were assay values and impurity levels within specification?
• Did turbidity, precipitation, or odor changes occur?
• Was the CCI consistently maintained?

Only containers that meet all acceptance criteria and show no adverse interactions should be qualified for commercial use.

Step 10: Document the Compatibility Assessment

For GMP and regulatory compliance, your documentation should include:

• Compatibility testing protocol with rationale and objectives
• Material and container specifications
• Stability data tables and chromatograms
• Risk assessments and justification of container choice
• Signed reports reviewed by QA/QC

Include these documents in Module 3 of your regulatory submission and ensure alignment with the packaging section of the CTD.

Common Issues and How to Avoid Them

• Using data from placebo or water-based simulants only—always test real product
• Overlooking stopper or cap compatibility—evaluate all container components
• Skipping E&L testing for non-sterile products—regulators expect it for all container types
• Inadequate sample size or missing timepoints—follow ICH statistical requirements

Refer to GMP guidelines to ensure best practices are followed during execution.

Conclusion

Container compatibility testing is a vital step in ensuring pharmaceutical product stability, safety, and compliance. By following a structured, risk-based approach that includes analytical testing, E&L evaluation, CCI assessment, and thorough documentation, pharma professionals can confidently qualify packaging materials. These efforts not only support robust stability programs but also facilitate smoother regulatory submissions and market approvals.

References:

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• USP : Assessment of Extractables
• USP : Container Closure Integrity Evaluation
• WHO Technical Report Series: Pharmaceutical Packaging
• FDA Guidance for Industry: Container Closure Systems